Pronai Therapeutics Stock News

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the compan

Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of myelofibrosis patients who are symptomatic and anemic. Momelotinib has a competitive advantage in

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaz

Sierra Oncology (SRRA) intends to undertake a $100M common stock offering.The company plans to grant the underwriters a 30-day option to buy up to $15M additional shares.Sierra intends

Sierra's long-shot blood cancer drug scores a big win in a pivotal-stage trial.

Sierra Oncology Inc (NASDAQ: SRRA ) unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-approved JAK inhibitor. With the new data in hand, Sierra now plans to submit a marketing application in Q2 FY22. In the Phase 3 study, 195 patients were randomized to receive either momelotinib or the control drug (danazol) for 24 weeks. Related: Full story available on Benzinga.com

Aptorum Group (APM) +39%. Sierra Oncology SRRA +36% says late-stage trial for momelotinib in myelofibrosis met key goals.Checkpoint Therapeutics CKPT +18% reports positive results

Sierra Oncology Inc. (NASDAQ: SRRA) shares are up 50% after the company announced a term loan deal with Oxford Finance LLC and the release of positive topline results from the vital Phase III MOMENTUM

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer, Inc. (NYSE: PFE) and BioNT

Sierra Oncology (SRRA) announced that the company’s pivotal Phase 3 study for its oral JAK inhibitor momelotinib ((MMB)) as a second-line option in myelofibrosis met all of its primary…

Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential launch of momelotinib.  The Company estimate

Sierra's long-shot blood cancer drug scores a big win in a pivotal-stage trial.

HC Wainwright restated their buy rating on shares of Sierra Oncology (NASDAQ:SRRA) in a report released on Friday, TipRanks reports. HC Wainwright currently has a $35.00 price target on the biotechnology companys stock. Other research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Sierra Oncology from a hold rating []